The monkeypox epidemic continues to ferment and another batch of monkeypox concept stocks have been discovered.

As of 21 May, 92 confirmed and 28 suspected cases of monkeypox have been reported in 12 non-monkeypox endemic countries. World Health Organization (WHO) predicts that the number of monkeypox cases worldwide may further increase. Bavarian Nordic BAVA, a pharmaceutical company based in Copenhagen, Denmark, said it had signed a contract with an unnamed European country to supply the smallpox vaccine Imvanex to deal with the monkeypox outbreak.

Monkeypox is a disease caused by a virus belonging to the same family as smallpox, but not as serious as smallpox, according to the Centers for Disease Control and Prevention (CDC). According to observational studies by the World Health Organization and the US CDC in Africa, the effectiveness of smallpox vaccine in preventing monkeypox is 85 per cent. The agency believes that preparations should be made in advance to strengthen the monitoring of cases with similar symptoms and develop diagnostic methods and reagents in order to detect imported cases in time, block transmission and prevent the epidemic of monkeypox in China.

According to the theme database of the Financial Associated Press, among the relevant listed companies:

$Beijing Tiantan Biological Products Corporation (600161.SH)$Tiantan Bio is the largest vaccine manufacturer in China, with pilot and clinical research projects for new smallpox vaccine.

$Beijing Konruns Pharmaceutical (603590.SH)$Kangchen Pharmaceutical is the only partner in Bavarian Nordic in China and parts of Asia. Bavarian Nordic is a long-term supplier of non-replicative smallpox vaccine approved by the U.S. Food and Drug Administration and used to prevent monkeypox.